Analytical Data
-
Gene name
BRMS1L
- Application
-
Alternative Names
BRMS1-homolog protein p40 （BRMS1-like protein p40）
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5PSV4
-
Expression Region
1-323aa
-
Molecular Weight
41.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRMS1L (Breast Cancer Metastasis Suppressor 1-Like) is a protein that has garnered significant attention in cancer research, particularly regarding its potential role in metastasis suppression. Originally identified as a candidate gene in breast cancer, BRMS1L has been implicated in various malignant cancers, suggesting a broader role in tumor biology. The research surrounding BRMS1L focuses on its functional mechanisms, particularly its influence on gene expression and cellular signaling pathways associated with cancer progression and metastasis. Studies have indicated that BRMS1L may impact the epithelial-mesenchymal transition (EMT), a critical process that endows cancer cells with the ability to invade neighboring tissues. Additionally, investigations into the molecular interactions of BRMS1L reveal potential pathways by which it may modulate tumor microenvironments and immune responses. Understanding the mechanistic pathways influenced by BRMS1L is crucial for developing targeted therapies and improving prognostic strategies in oncology. As metastatic disease remains a leading cause of cancer-related mortality, unraveling the functions of BRMS1L presents opportunities for novel therapeutic interventions that could mitigate cancer spread and enhance patient outcomes. The ongoing exploration of this protein's role in various cancer types emphasizes its potential as a biomarker and therapeutic target, underscoring the importance of continued research in this area.
